The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
News|Slideshows|February 1, 2022
Omicron Subvariant BA.2: What We Know Now
Author(s)Grace Halsey
Known as BA.2, the new Omicron subvariant is now circulating at low levels in the US. What can you tell your patients? Here's what we know, now.
Advertisement
The COVID-19 Omicron subvariant, known as BA.2, is circulating in the US at "low levels," according to the Centers for Disease Control and Prevention. About half the states have confirmed its presence, with about 127 cases identified as of today.
But in Denmark the subvariant represents more than 80% of cases seen. Case numbers are creeping up in the UK, and BA.2 is becoming the dominant Omicron strain in the Philippines, Nepal, Qatar, and India.
While all data remain preliminary, they point to the potential for an infection that is even more transmissable than the original Omicron strain , BA.1, but not any more infectious. Following is a topline look at what we know now.
Advertisement
Related to this article
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
Advertisement
Advertisement
Trending on Patient Care Online
1
Mediterranean Diet Linked to Lower Odds of Adult Acne in New Study
2
4 FDA Decisions for Primary Care to Know from October 2026
3
Why a Negative Endometrial Biopsy May Not End the Abnormal Bleeding Workup
4
FDA Clears 15-Minute Blood Test to Help Distinguish Bacterial From Viral Infections
5